A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

Overview

The purpose of this study is to evaluate the long-term (6-month) efficacy, safety, and tolerability of alprazolam XR in adolescents with panic disorder.

Full Title of Study: “A Randomized, Double-blind, Placebo-controlled Study of Continuation Treatment With Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)

Detailed Description

Due to recruitment difficulties in this adolescent population, the clinical program for alprazolam XR was cancelled and this study was terminated on 1 September 2004. There were no safety concerns that led to this decision.

Interventions

  • Other: placebo
    • Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
  • Drug: alprazolam XR
    • Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo group
  • Active Comparator: Alprazolam XR group

Clinical Trial Outcome Measures

Primary Measures

  • Baseline-to-peak Physician Withdrawal Checklist change score during taper off Alprazolam
    • Time Frame: Week 24 (taper baseline), Weeks 25-29, and end of taper visit
  • The incidence of treatment-emergent adverse events during 6 months of treatment with alprazolam XR
    • Time Frame: Weeks 6, 8, 12, 16, 20, and 24
  • Endpoint change from baseline in Digit Symbol-Coding Test, immediate recall, and delayed recall
    • Time Frame: Week 24

Secondary Measures

  • Endpoint change from baseline in Hamilton Anxiety Rating scale
    • Time Frame: Weeks 12 and 24
  • Endpoint change compared with baseline in the Panic Disorder Severity Scale – Adolescent Version total and item scores
    • Time Frame: Weeks 12 an 24
  • Endpoint compared with baseline for Clinical Global Impression (CGI)-Improvement scale
    • Time Frame: Weeks 12 and 24
  • Endpoint change compared with baseline in CGI-Severity score
    • Time Frame: Weeks 12 and 24
  • Endpoint compared with baseline in Pediatric Quality of Life, Enjoyment, and Satisfaction Questionnaire improvement score
    • Time Frame: Weeks 12 and 24
  • Descriptive estimates of the persistence of safety events and adverse events
    • Time Frame: Week 24

Participating in This Clinical Trial

Inclusion Criteria

  • A primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis of panic disorder with or without agoraphobia based on the Mini-International Neuropsychiatric Interview for Children and Adolescents – Subjects with an average of 1) at least one 4-symptom panic attack per week over the last 4 weeks before screening; 2) at least one 4-symptom panic attack per week over the last 4 weeks before baseline; and 3) at least one 4-symptom panic attack in the 7 days prior to baseline – To enter Study A6131007, subjects must have completed Study A6131002, had an acceptable tolerability to study drug, and in the clinical judgment of the investigator, could have benefited from continued study treatment. Exclusion Criteria:

  • Subjects must continue to meet all of the exclusion criteria enumerated in the Acute Efficacy Study (Protocol A6131002) with the following exception: Subjects will be allowed to undergo cognitive-behavioral or other panic-specific therapy and any other psychotherapy (e.g., supportive and/or family therapy) during the expected study period in this study.

Gender Eligibility: All

Minimum Age: 13 Years

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pfizer’s Upjohn has merged with Mylan to form Viatris Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pfizer CT.gov Call Center, Study Director, Pfizer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.